Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDH1
REST API REST API
Homo sapiens
CDH1 is differentially expressed in 294 experiments: 186 organism parts: prostate, liver, ... (184 more);, 226 disease states: normal, prostate carcinoma, ... (224 more);, 120 cell types 618 cell lines 38 compound treatments and 81 other conditions.
Synonyms uvomorulin, CD324, UVO
Orthologs F1MCJ4_BOVIN (Bos taurus)   Cdh1 (Mus musculus)   si:dkey-173l11.5 (Danio rerio)   si:dkey-30c15.12 (Danio rerio)   cdh1 (Danio rerio)   si:ch211-206i14.2 (Danio rerio)   Cdh1 (Rattus norvegicus)   cdh1 (Xenopus laevis)   Q0IIT0_XENTR (Xenopus laevis)   si:dkey-173l11.3 (Danio rerio)   Q95LE0_CANFA (Canis familiaris)   CadN2 (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term focal adhesion, plasma membrane, adherens junction organization, protein binding, synapse assembly, apoptosis, cell-cell adherens junction, cytoplasm, cell-cell adhesion, beta-catenin binding, response to toxin, membrane, homophilic cell adhesion, protein homooligomerization, cell-cell junction organization, Golgi apparatus, protein domain specific binding, cell adhesion molecule binding, cell junction, basolateral plasma membrane, cell adhesion, actin cytoskeleton, neuron projection development, positive regulation of transcription factor import into nucleus, endosome, response to drug, perinuclear region of cytoplasm, apical part of cell, integral to membrane, cell surface, apical junction complex, protein metabolic process, GTPase activating protein binding, lateral plasma membrane, positive regulation of transcription, DNA-dependent, calcium ion binding, regulation of immune response, pituitary gland development, internal side of plasma membrane, RPTP-like protein binding, in utero embryonic development, negative regulation of cell-cell adhesion, gamma-catenin binding, node of Ranvier, cellular response to lithium ion, regulation of branching involved in salivary gland morphogenesis, cellular response to indole-3-methanol, catenin complex, lateral loop, response to organic substance, protein phosphatase binding, salivary gland cavitation, trophectodermal cell differentiation, aggresome, tight junction assembly, cellular component disassembly involved in apoptosis, regulation of protein localization at cell surface, cellular response to amino acid stimulus, regulation of water loss via skin, Schmidt-Lanterman incisure, cell junction assembly, regulation of cysteine-type endopeptidase activity involved in apoptotic process
InterPro Term Cadherin, Cadherin_cytoplasmic-dom, Cadherin_pro
Gene-Disease Assocation OVARIAN CANCER, PROSTATE CANCER, ENDOMETRIAL CANCER, BREAST CANCER, GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC
UniProt Accession Q9UII7, Q9UII8, P12830, B3GN61, A8K1U7, F5GYI6
Search EB-eye ENSG00000039068
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-2361, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
SW480
4
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509, E-MTAB-37
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
U251
2
E-GEOD-20089, E-MTAB-62
BT20
2
E-MTAB-37, E-MTAB-62
HCC2157
2
E-MTAB-37, E-MTAB-62
612 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, ... (56 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
endothelial cell
1
2
E-GEOD-3920, E-GEOD-3998, E-GEOD-19240
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-2248, E-GEOD-26672
CD4+ T cell
1
2
E-MEXP-1600, E-AFMX-5, E-MTAB-24
114 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, E-MTAB-680, ... (56 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
5
E-MTAB-62, E-MTAB-37, E-GEOD-7307, E-GEOD-96, E-MEXP-1327, ... (6 experiments)
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
acute promyelocytic leukemia
3
E-GEOD-1729, E-MTAB-62, E-GEOD-995
lymphoma
2
E-MTAB-62, E-MTAB-37
benign prostatic hyperplasia
2
E-GEOD-7307, E-MEXP-2034
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
220 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-GEOD-15811, ... (23 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-5230, E-GEOD-412, E-MEXP-1269, E-GEOD-995, E-TABM-782, ... (9 experiments)
5-aza-2'-deoxycytidine
3
2
E-GEOD-5230, E-MEXP-1269
5-aza-2'-deoxycytidine + trichostatin A
2
2
E-MEXP-1269, E-GEOD-5230
Cxcl12
1
E-GEOD-7307
lipopolysaccharide
1
E-MEXP-1958
heregulin
1
E-GEOD-6462
32 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847

Genotype
studied in E-GEOD-2152, E-TABM-1029, E-GEOD-22056, E-GEOD-2466, E-GEOD-2292, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-MEXP-1446, E-MEXP-1741, E-MEXP-1273, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2657, E-MEXP-2069, E-GEOD-1926, ... (38 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-GEOD-360

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.504 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM